BioNTech to Acquire CureVac for $1.25B in All-Stock mRNA Oncology Deal

Published on Spencer Knight via LinkedIn

BioNTech has signed a definitive agreement to acquire CureVac in an all-stock transaction valued at approximately $1.25 billion. CureVac shareholders will receive BioNTech ADS shares valued at $5.46 each, reflecting a 55% premium.

The deal expands BioNTech’s mRNA-based cancer immunotherapy pipeline and complements its mRNA design, manufacturing, and formulation strengths. Post-close, CureVac shareholders will own up to 4–6% of BioNTech. The acquisition is expected to finalize in 2025.

Spencer Knight highlights this as a landmark moment uniting two leading German innovators in mRNA and cancer immunotherapy. It also reinforces investor confidence in next-gen delivery technologies and tumor-targeted design platforms.

Read the full post on LinkedIn:

👉 Spencer Knight: BioNTech to Acquire CureVac for $1.25 Billion

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.